GHS1128

Hematoxylin Solution, Gill No. 1

Name: Hematoxylin Solution, Gill No. 1
Brand: SIGMA

Select a Size

All Photos(2)

About This Item

NACRES:

NA.47

PubChem Substance ID:

24895387

UNSPSC Code:

41116124

MDL number:

MFCD00078111

InChI

1S/C16H14O6/c17-10-2-1-8-13-9-4-12(19)11(18)3-7(9)5-16(13,21)6-22-15(8)14(10)20/h1-4,13,17-21H,5-6H2/t13-,16+/m0/s1

SMILES string

Oc1cc2C[C@@]3(O)COc4c(O)c(O)ccc4[C@H]3c2cc1O

InChI key

WZUVPPKBWHMQCE-XJKSGUPXSA-N

form

solution

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

concentration

2 g/L

pH

2.5-3.5

application(s)

hematology
histology

storage temp.

room temp

Quality Level

500

Looking for similar products? Visit Product Comparison Guide

Related Categories

Clinical & Diagnostics

Application

Gill No. 1 formulation is used as a progressive cytology stain. Used with hematoxylin and eosin staining.

Other Notes

2 g/L certified hematoxylin

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H302,H373

pcodes

P260 - P264 - P270 - P301 + P312 - P314 - P501

Hazard Classifications

Acute Tox. 4 Oral - STOT RE 2 Oral

target_organs

Kidney

Storage Class

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.

Michael J Turner et al.

Journal of neuroimmunology, 285, 4-12 (2015-07-23)

Alemtuzumab, a monoclonal antibody directed against human CD52, is used in the treatment of MS. To characterize the impact of anti-CD52 administration, a monoclonal antibody to mouse CD52 (anti-muCD52) was generated and evaluated in EAE mouse models of MS. A

Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.

Eleni Maniati et al.

Cell reports, 30(2), 525-540 (2020-01-16)

Although there are many prospective targets in the tumor microenvironment (TME) of high-grade serous ovarian cancer (HGSOC), pre-clinical testing is challenging, especially as there is limited information on the murine TME. Here, we characterize the TME of six orthotopic, transplantable syngeneic

Synthesis and biological evaluation of deoxy-hematoxylin derivatives as a novel class of anti-HIV-1 agents.

Hideki Ishii et al.

Bioorganic & medicinal chemistry letters, 22(3), 1469-1474 (2012-01-17)

SAR studies for the exploration a novel class of anti-human immunodeficiency virus type 1 (HIV-1) agents based on the hematoxylin structure (1) are described. The systematic deoxygenations of 1 including asymmetric synthesis were conducted to obtain a compound showing high

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.

Devalingam Mahalingam et al.

Autophagy, 10(8), 1403-1414 (2014-07-06)

We previously reported that inhibition of autophagy significantly augmented the anticancer activity of the histone deacetylase (HDAC) inhibitor vorinostat (VOR) through a cathepsin D-mediated mechanism. We thus conducted a first-in-human study to investigate the safety, preliminary efficacy, pharmacokinetics (PK), and

Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.

Li-Gen Lin et al.

Journal of medicinal chemistry, 51(15), 4419-4429 (2008-07-10)

Protein tyrosine kinase (PTK) inhibitors represent emerging therapeutics for cancer chemoprevention. In our study, hematoxylin (26) was identified as one of the most remarkable c-Src inhibitors in an orthogonal compound-mixing library (32200 compounds) by using an ELISA-based automated high-throughput screening